GC Biopharma Plant Obtains WHO Pre-Qualification

Article

South Korea facility expected to provide fill-finish capabilities.

The World Health Organization (WHO) has awarded prequalification to GC Biopharma, a biopharma company, for its fill-finish plant. Located in Ochang, South Korea, the complex is expected to produce drug products for vaccines (including sterile vials and pre-filled syringes), along with non-vaccine fill-finish and packaging. Established in 2019, the site is reportedly the largest fill-finish facility in the country.

According to the company, the new plant is equipped with an isolator facility and automation capabilities that power the entire process; it also employs a single-use system. GC Biopharma has supplied flu vaccines annually for the past three years through the Pan American Health Organization (PAHO) and the United Nations Children’s Fund (UNICEF).

“We hope [to] contribute to advancing global public health, based on our know-how and manufacturing capabilities that have produced and supplied vaccines for half a century," says EC Huh, PhD, president of GC Biopharma.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.